The 90% Effective Sedation Dose Of Midazolam

• Status: Unknown status
• Trial end date: 2019-12-15
• Target enrollment: 0
• Participant gender: All

Summary

There are no clear conclusive clinical reports defining the adequate effective dose of midazolam in patients undergoing day-case esophageal-gastro-duodenoscopy (EGD). Defining such dosage will facilitate practitioners who are not anesthesia professionals to administer sedative drugs to establish a satisfactory level of moderate sedation. Our first aim is to determine the effective dose for 90% of patients (ED 90) of midazolam undergoing day-case EGD.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Fahad Specialist Hospital Dammam
• Treatments: Midazolam

Criteria

Inclusion Criteria:

• ASA 1&2

Exclusion Criteria:

1. Patients with hypersensitivity to midazolam,

2. Age less than 18,

3. Obstructive sleep apnea

4. known or suspected memory impairment,

5. Patients with psychiatric disorders,

6. visual or hearing impairment and pregnancy